COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Radiation Therapy With or Without Temozolomide in Treating Women With Brain Metastases and Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00875355
Recruitment Status : Unknown
Verified July 2009 by National Cancer Institute (NCI).
Recruitment status was:  Recruiting
First Posted : April 3, 2009
Last Update Posted : August 26, 2009
Information provided by:
National Cancer Institute (NCI)

Brief Summary:

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether radiation therapy is more effective when given alone or together with temozolomide in treating brain metastases secondary to breast cancer.

PURPOSE: This randomized phase II trial is studying how well radiation therapy given together with temozolomide works compared with radiation therapy given alone in treating women with brain metastases and breast cancer.

Condition or disease Intervention/treatment Phase
Breast Cancer Metastatic Cancer Drug: temozolomide Radiation: radiation therapy Phase 2

Detailed Description:



  • Compare the objective response rate at 6 weeks in women with brain metastases secondary to breast cancer treated with radiotherapy with vs without temozolomide.


  • Evaluate the tolerability.
  • Compare the duration of response.
  • Compare local progression-free survival.
  • Compare overall survival.

OUTLINE: This is a multicenter study. Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients undergo isocentric radiotherapy to the brain 5 times a week for 2 weeks.
  • Arm II: Patients undergo radiotherapy as in arm I and receive oral temozolomide once daily for 2 weeks.

After completion of study treatment, patients are followed at 3 and 6 months and then every 6 months for 2 years.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Primary Purpose: Treatment
Official Title: Phase II Randomized Multicenter Study Comparing Brain Radiation in Combination With Temozolomide or Radiation Alone in Patients With Brain Metastases From Breast Cancer
Study Start Date : November 2007
Estimated Primary Completion Date : November 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Arm I
Patients undergo isocentric radiotherapy to the brain 5 times a week for 2 weeks.
Radiation: radiation therapy
Patients undergo radiotherapy

Experimental: Arm II
Patients undergo radiotherapy as in arm I and receive oral temozolomide once daily for 2 weeks.
Drug: temozolomide
Given orally

Radiation: radiation therapy
Patients undergo radiotherapy

Primary Outcome Measures :
  1. Response at 6 weeks as assessed by MRI and/or scan

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No


  • Diagnosis of breast cancer

    • Unresectable disease or patient refused surgery
  • Must have brain metastases


  • WHO performance status 0-2
  • ANC ≥ 1,500/mm³
  • Platelet count ≥ 100,000/mm³
  • Liver transaminases ≤ 1.5 times upper limit of normal (ULN)
  • Creatinine < 1.5 times ULN
  • Not pregnant or nursing
  • Fertile patients must use effective contraception
  • No carcinomatous meningitis
  • No history of cancer except for basal cell carcinoma of the skin or carcinoma in situ of the cervix
  • No other serious concurrent disease that is, in the opinion of the investigator, likely to interfere with study evaluation and treatment
  • No contraindications to treatment with temozolomide
  • No psychological, familial, social, or geographic situations that preclude clinical follow up
  • No patient deprived of liberty or under guardianship


  • No prior brain radiotherapy
  • At least 10 days since prior chemotherapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00875355

Layout table for location information
Institut Curie Hopital Recruiting
Paris, France, 75248
Contact: Youlia Kirova    33-44-32-4000      
Sponsors and Collaborators
Institut Curie
Layout table for investigator information
Principal Investigator: Youlia Kirova Institut Curie
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information Identifier: NCT00875355    
Other Study ID Numbers: CDR0000633496
First Posted: April 3, 2009    Key Record Dates
Last Update Posted: August 26, 2009
Last Verified: July 2009
Keywords provided by National Cancer Institute (NCI):
tumors metastatic to brain
stage IV breast cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents